ArticleUrology2026
Fear of Cancer Recurrence Among Uninsured and Underrepresented Men With Prostate Cancer.
Article in Urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveTo characterize the prevalence of fear of cancer recurrence (FCR) and examine demographic, clinical, and psychosocial factors associated with high FCR among low-income, racially and ethnically diverse prostate cancer survivors treated with definitive therapy for localized disease.
methodsWe conducted a retrospective, cross-sectional analysis of 150 participants enrolled in the Men's Health Study (2001-2007) who completed the FCR Survey at baseline. High FCR was defined as a score ≤14 (lower tertile). Demographic, clinical, and patient-reported outcomes were assessed, including health-related quality of life (SF-12v2), prostate-specific quality of life (PCI-SF), symptom distress, spirituality, patient-physician interaction (PEPPI), and treatment regret.
resultsHigh FCR was reported by 28% of participants. Sociodemographic and clinical variables-including age, race/ethnicity, treatment, clinical T stage, grade, PSA, and comorbidities-were not associated with FCR. High FCR correlated strongly with poorer mental health, lower SF-12 mental composite scores, and emotional limitations. Treatment regret was significantly more prevalent among those with high FCR (95.2% vs 28.7%, P<.001). Physical health and prostate-specific quality of life did not differ by FCR level.
conclusionNearly one-third of uninsured, underrepresented prostate cancer survivors experienced high FCR, driven by emotional distress and decisional regret rather than objective clinical risk, underscoring the need for equitable, patient-centered survivorship care that supports psychological well-being and promoting patient informed decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.